Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) EPS (Basic) (2024 - 2025)

Kairos Pharma (KAPA) has disclosed EPS (Basic) for 2 consecutive years, with -$0.08 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EPS (Basic) fell 300.0% year-over-year to -$0.08, compared with a TTM value of -$0.34 through Jun 2025, changed N/A, and an annual FY2024 reading of -$0.23, down 35.29% over the prior year.
  • EPS (Basic) was -$0.08 for Q2 2025 at Kairos Pharma, roughly flat from -$0.08 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.02 in Q2 2024 and bottomed at -$0.1 in Q3 2024.